RxDoctor Payments Data

Phillip Koren, MD

Cardiovascular Disease · Camden, NJNPI 1831142207

Payments from drug & device makers

$5,131in general payments, 2019–2025

Across 111 payments — averaging $46.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$2K
  • Atricure, Inc.$791
  • Abbott$779
  • Biosense Webster, Inc.$339
  • Abiomed$250
  • Novartis$143
  • plus $797 from 13 others

What the payments were for

  • Travel & lodging$1,04620%
  • Food & beverage$4,08580%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,131 in reported general payments places this provider in the 65th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$59,190
Medicare patients
246
Services billed
745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban50$64,708
Repatha SureclickEvolocumab36$45,931
EntrestoSacubitril/Valsartan32$37,284
XareltoRivaroxaban13$15,587
Rosuvastatin Calcium180$2,259
Metoprolol Succinate92$1,633
Atorvastatin Calcium135$1,591
ClopidogrelClopidogrel Bisulfate68$901
Losartan Potassium72$757
Amlodipine Besylate95$709
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide23$611
Valsartan13$532
Ranolazine ErRanolazine11$526
Nitroglycerin14$508
Furosemide40$326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$44$64,70850 claims
NovartisEntresto$143$37,28432 claims
Johnson & JohnsonXarelto$29$15,58713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →